Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
64 hedge funds and large institutions have $35.6M invested in Asterias Biotherapeutics Inc. Series A in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
95% more capital invested
Capital invested by funds: $18.3M → $35.6M (+$17.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 66 → 64 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
+$2.26M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$518K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$337K |
| 4 |
State Street
Boston,
Massachusetts
|
+$194K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$189K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$999K |
| 2 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$61K |
| 3 |
SG Americas Securities
New York
|
-$53K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$34K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$21.8K |
AST Hedge Fund Activity: Q3 2016 in Review
64 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q3 2016, worth a combined $35.6M — up 95% from $18.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AST and 3 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 20 added.
The largest buyer was Northeast Financial Consultants, adding an estimated $2.26M. The largest seller was Sabby Management, exiting entirely with an estimated $999K sold.
- 64 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q3 2016, down from 66 in Q2 2016.
- Funds reported $35.6M of Asterias Biotherapeutics Inc. Series A stock for Q3 2016, up 95% quarter-over-quarter.
- 3 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q3 2016 and 4 closed out, a net change of -1 holder.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q3 2016 was Northeast Financial Consultants, an estimated $2.26M added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q3 2016 was Sabby Management, an estimated $999K sold.
Based on aggregated 13F filings for Q3 2016.